Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 
Press Release
 View printer-friendly version << Back

BIO Welcomes David Schenkein, M.D., to the Emerging Companies Section Governing Board

BIO Welcomes New Executive Committee and Section Governing Board Members

2012 BIO International Convention

WASHINGTON--The Board of Directors of the Biotechnology Industry Organization (BIO) elected its Executive Committee and added new members to Section Governing Boards in a meeting held in conjunction with the 2012 BIO International Convention, the global event for biotechnology, taking place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA.

“We are pleased to welcome the new members of the Executive Committee and Section Governing Boards,” stated BIO President and CEO Jim Greenwood. “Their new perspectives and ideas are valuable additions to the collective expertise of the BIO Board as we advocate for public policy in the U.S. and around the world that encourages the research and development necessary for continued innovation in breakthrough medical therapies, enhanced agricultural products and revolutionary biofuels.”

H. Thomas Watkins, President and CEO of Human Genome Sciences, Inc., will continue to serve as the Chair of the Board of Directors and of the Health Section Governing Board.


The full BIO Board of Directors is comprised of the elected Directors serving on each of BIO’s Section Governing Boards (Emerging Companies, Food and Agriculture, Health, and Industrial and Environmental). The newly-elected Board Members from these sections are:

Emerging Companies Section Governing Board
Arlene Morris, Chief Executive Officer, Syndax Pharmaceuticals, Inc.
Mike Naraci, Chief Executive Officer, Orexigen Therapeutics, Inc.
David Schenkein, Chief Executive Officer, Agios Pharmaceuticals, Inc.
Moncef Slaoui, Chairman, Research & Development, GlaxoSmithKline, plc


About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.